Mike Aperghis

Mike Aperghis is a Senior Director and Global Development Scientist specializing in Immuno-Oncology at AstraZeneca, where they are involved in both early and late-phase development of bi-specific monoclonal antibodies for NSCLC and colorectal cancer. Previously, Mike held significant roles at various organizations, including Senior Scientist at GlaxoSmithKline and Clinical Scientist at ONO Pharmaceutical Co., focusing on neurodegenerative diseases and early clinical development. Mike earned a BSc in Pharmacology from the University of Leeds, an MSc in Toxicology from the University of Birmingham, and a PhD in Neuroscience from UCL. Currently, Mike is pursuing an MSc in Epidemiology while continuing their impactful contributions to the field.